EASEE(R)


Associated tags: Cochlear, Education, Medical imaging, Medical device, Pharmaceutical industry, Quality of life, CTO, Scalp, Bone conduction, Federal Ministry of Health (Germany), MD, Hearing loss, Cochlear Limited, CE marking, Electrode, Research, Patient, Movement, AUD, Vagus nerve stimulation

DGAP-News: Precisis concludes funding round of €20 million for its bioelectric brain stimulation system

Retrieved on: 
Thursday, October 14, 2021
Cochlear, CE marking, Achievement, Epilepsy, EURO, German, Brain, Marketing, Vagus nerve stimulation, AUD, Movement, Patient, Research, Electrode, CEO, Cochlear Limited, Education, Hearing loss, MD, Federal Ministry of Health (Germany), Bone conduction, Scalp, CTO, Quality of life, Pharmaceutical industry, Medical device, Medical imaging, Borosilicate glass

Heidelberg, Germany, [14 October 2021] - Precisis AG, based in Heidelberg, announced that it has successfully concluded a funding round of 20 million with Cochlear Limited.

Key Points: 
  • Heidelberg, Germany, [14 October 2021] - Precisis AG, based in Heidelberg, announced that it has successfully concluded a funding round of 20 million with Cochlear Limited.
  • Precisis is a medical technology company that develops minimally invasive brain stimulation methods to relieve epilepsy patients from their symptoms.
  • The additional funding will be used to support ongoing clinical studies and to further advance EASEE(R), an implantable bioelectric brain stimulation system that explores novel approaches to treating epilepsy.
  • Angela Liedler, MD, CEO of Precisis AG, is thrilled: "This funding round is an important step in the advancement of bioelectric brain stimulation.